

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 28, 2003, 18:21:02 ; Search time 40.1818 seconds  
(without alignments)  
51.353 Million cell updates/sec

Title: US-09-743-225-10  
Perfect score: 66  
Sequence: 1 CATLRVYKGGXA 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : A\_Geneseq\_19Jun03:\*

1: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.\*  
2: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.\*  
3: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.\*  
4: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.\*  
5: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.\*  
6: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.\*  
7: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.\*  
8: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.\*  
9: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.\*  
10: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.\*  
11: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.\*  
12: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.\*  
13: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.\*  
14: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.\*  
15: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.\*  
16: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.\*  
17: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.\*  
18: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.\*  
19: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.\*  
20: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA1999.DAT.\*  
21: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.\*  
22: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.\*  
23: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.\*  
24: /SIDSL/gcgdata/geneseq/geneseq-emb1/AA2003.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	64	97.0	13	21	AA199261
2	55	83.3	10	21	AA17996
3	55	83.3	10	21	AA19274
4	55	83.3	10	23	ABB7367
5	46	69.7	9	21	AA17995
6	46	69.7	9	23	ABB7366
7	38	57.6	112	22	AAU46530
8	38	57.6	266	21	AA19912
9	38	57.6	266	21	AA19915

10	38	57.6	283	21	AA19911	Arabidopsis thalia
11	38	57.6	283	21	AA19914	Arabidopsis thalia
12	38	57.6	333	21	AA19910	Arabidopsis thalia
13	38	57.6	333	21	AA19915	Arabidopsis thalia
14	37	56.1	55	22	AA19913	Novel human diago
15	37	56.1	206	24	AA19914	Human adipocyte se
16	37	56.1	896	22	AA19913	Novel bone marrow
17	37	56.1	980	22	AA19918	Human protein sequ
18	37	56.1	1104	24	AA19914	Human expressed pr
19	37	56.1	1104	24	AA19914	Human expressed pr
20	37	56.1	1104	24	AA19914	Human expressed pr
21	37	56.1	1435	21	AA19913	Human OREF ORF157
22	36	54.5	63	22	AA19913	Propionibacterium
23	36	54.5	71	21	AA19913	Arabidopsis thalia
24	36	54.5	79	21	AA19913	Arabidopsis thalia
25	36	54.5	145	22	AA19913	Drosophila melanog
26	36	54.5	148	23	AA19913	Human polypeptide
27	36	54.5	166	23	AA19913	Helicobacter pylor
28	36	54.5	343	21	AA19913	Xylitol dehydrogen
29	36	54.5	367	22	AA19913	Drosophila melanog
30	36	54.5	368	24	AA19913	Human novel polype
31	36	54.5	376	22	AA19913	Novel human diago
32	36	54.5	398	24	AA19913	Human secretory po
33	36	54.5	687	23	AA19913	Prostate cancer-as
34	36	54.5	4529	23	AA19913	Mouse alpha2 macro
35	36	54.5	4545	23	AA19913	Mouse alpha 2 macr
36	35	53.0	14	20	AA19913	Cysteine noose lib
37	35	53.0	23	23	AA19913	Phosducin peptide
38	35	53.0	106	21	AA19913	Arabidopsis thalia
39	35	53.0	106	21	AA19913	Arabidopsis thalia
40	35	53.0	148	22	AA19913	Human bone marrow
41	35	53.0	257	20	AA19913	Protein involved i
42	35	53.0	259	20	AA19913	Clonorchis sinensi
43	35	53.0	286	14	AA19913	34 kDa crystal pro
44	35	53.0	340	14	AA19913	40 kDa crystal pro
45	35	53.0	367	22	AA19913	Novel human diago

#### ALIGNMENTS

RESULT 1  
AA199261  
ID AA199261 standard; peptide; 13 AA.  
AC AA199261;  
XX  
XX 30-MAY-2000 (first entry)  
DT  
DE Monopeptide which inhibits anti-beta-2-glycoprotein 1 antibodies.  
XX  
XX Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody;  
KW anti-phospholipid syndrome; anti-phospholipid antibody;  
KW pregnancy complication; thrombosis; coagulation dysregulation.  
XX  
XX Synthetic.  
XX  
FH Key Location/Qualifiers  
FT Modified-site 12  
FT /note= "FmocLys(Fmoc)-OH"  
XX  
XX WO200001729-A2.  
XX  
XX 13-JAN-2000.  
PD  
XX 06-JUL-1999; 99WO-IL00366.  
XX  
XX 07-JUL-1998; 98IL-0125262.  
XX  
XX (YEDA ) YEDA RES & DEV CO LTD.  
XX  
XX Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;  
XX

DR WPI; 2000-182105/16.  
 XX Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1  
 PT antibodies, useful for diagnosis and treatment of anti-phospholipid  
 PT syndrome in humans  
 XX Disclosure; Page 13; 58pp; English.  
 PS  
 CC The present sequence represents a synthetic peptide which is capable  
 CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1  
 CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo  
 CC induction of experimental anti-phospholipid syndrome in mice by  
 CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis  
 CC and treatment of anti-phospholipid syndrome. They may also be used  
 CC for the diagnosis of anti-phospholipid antibodies with different  
 CC pathogenic biofunctions which may correlate with either pregnancy  
 CC complications, thrombosis or coagulation dysregulation.  
 XX  
 SQ Sequence 13 AA;  
 Query Match 97.0%; Score 64; DB 21; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 0.00019;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CATLRYKGGXA 13  
 Db | | | | | | | | | | | | | |  
 1 CATLRYKGGXA 13  
 RESULT 2  
 AAB17996  
 ID AAB17996 standard; Peptide; 10 AA.  
 XX  
 AC AAB17996;  
 XX  
 DT 31-OCT-2000 (first entry)  
 XX  
 DE Membrane-transporting peptide sequence SEQ ID NO:1108.  
 XX  
 KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;  
 KW autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;  
 KW immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;  
 KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;  
 KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;  
 KW vascular endothelial growth factor; matrix metalloproteinase;  
 KW asthma; thrombosis; pharmaceutical.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200024782-A2.  
 XX  
 PD 04-MAY-2000.  
 XX  
 PF 25-OCT-1999; 99WO-US25044.  
 XX  
 PR 23-OCT-1998; 98US-0105371.  
 PR 22-OCT-1999; 99US-0428082.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX  
 PI Felge U, Liu C, Cheatham J, Boone TC;  
 XX  
 DR WPI; 2000-350702/30.  
 XX  
 CC Novel composition of matter comprising an Fc domain and  
 PT pharmacologically active peptides, useful for treating cancer and  
 PT autoimmune diseases  
 XX  
 PS Claim 39; Page 601; 608pp; English.  
 XX  
 CC The present invention describes composition of matter (I) comprising an  
 CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:  
 CC (X1)a-Fl-(X2)b, where: Fl = an Fc domain; X1 and X2 = are each

CC independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,  
 CC -(L1)c-P1-(L2)d-P2-(L3)e-P3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4  
 CC where P1, P2, P3, and P4 = are each independently sequences of  
 CC pharmacologically active peptides; L1, L2, L3, and L4 = are each  
 CC independently linkers; and a, b, c, d, e, and f = are each independently  
 CC 0 or 1, provided that at least 1 of a and b is 1. The composition can  
 CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive  
 CC activities. DNAs, vectors and host cells from the present invention can  
 CC be used for producing pharmaceutical compositions. The compositions are  
 CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.  
 CC The use of an Fc domain (rather than a Fab domain) can provide a longer  
 CC half-life or incorporate functions such as Fc receptor binding, protein  
 CC binding, complement fixation, and possibly placental transfer. AAB69443  
 CC to AAB69526 and AAB16955 to AAB18003 represent nucleotide and amino acid  
 CC sequences used in the exemplification of the present invention.  
 XX  
 SQ Sequence 10 AA;  
 Query Match 83.3%; Score 55; DB 21; Length 10;  
 Best Local Similarity 100.0%; Pred. No. 0.0052;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 CATLRYKGG 10  
 Db | | | | | | | | | |  
 1 CATLRYKGG 10  
 RESULT 3  
 AAY69274  
 ID AAY69274 standard; peptide; 10 AA.  
 XX  
 AC AAY69274;  
 XX  
 DT 30-MAY-2000 (first entry)  
 XX  
 DE Peptide which inhibits anti-beta-2-glycoprotein 1 antibodies.  
 XX  
 KW Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody;  
 KW anti-phospholipid syndrome; anti-phospholipid antibody;  
 KW pregnancy complication; thrombosis; coagulation dysregulation.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200001729-A2.  
 XX  
 PD 13-JAN-2000.  
 XX  
 PF 06-JUL-1999; 99WO-IL00366.  
 XX  
 PR 07-JUL-1998; 98IL-0125262.  
 XX  
 PA (YEDA ) YEDA RES & DEV CO LTD.  
 XX  
 PI Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;  
 XX  
 DR WPI; 2000-182105/16.  
 XX  
 PT Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1  
 PT antibodies, useful for diagnosis and treatment of anti-phospholipid  
 PT syndrome in humans  
 XX  
 PS Claim 5; Page 38; 58pp; English.  
 XX  
 CC The present sequence represents a synthetic peptide which is capable  
 CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1  
 CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo  
 CC induction of experimental anti-phospholipid syndrome in mice by  
 CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis  
 CC and treatment of anti-phospholipid syndrome. They may also be used  
 CC for the diagnosis of anti-phospholipid antibodies with different  
 CC pathogenic biofunctions which may correlate with either pregnancy  
 CC complications, thrombosis or coagulation dysregulation.  
 XX

SQ Sequence 10 AA;  
 Query Match 83.3%; Score 55; DB 21; Length 10;  
 Best Local Similarity 100.0%; Pred. No. 0.0052;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CATLRVYKGG 10  
 Db 1 CATLRVYKGG 10

RESULT 4  
 ABB73367  
 ID ABB73367 standard; Peptide; 10 AA.  
 XX AC ABB73367;  
 XX DT 05-APR-2002 (first entry)  
 XX DE Exemplary pharmacologically active peptide SEQ ID NO:1106.  
 XX KW Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;  
 KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;  
 KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;  
 KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;  
 KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;  
 KW cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;  
 KW antianaemic; anorectic; antifertility; haemostatic; dermatological;  
 KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;  
 KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;  
 KW sleep disorder; neurological degenerative disease; anaemia;  
 KW thrombocytopenia; metastatic tumour; systemic lupus erythematosus;  
 KW Fanconi's syndrome.  
 XX OS Synthetic.  
 XX WO200183525-A2.  
 XX PN 08-NOV-2001.  
 XX PD 02-MAY-2001; 2001WO-US14310.  
 XX PF 03-MAY-2000; 2000US-0563286.  
 XX PR (AMGE-) AMGEN INC.  
 XX PA Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;  
 XX PI WPI; 2002-130313/17.  
 XX DR Novel vehicle-peptide molecule or its multimers useful for treating  
 XX PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,  
 XX PT diabetic retinopathy, obesity, sleep disorders and infertility -  
 XX PS Claim 39; Page 62; 176pp; English.  
 XX CC The present invention describes a vehicle-peptide molecule (I) or its  
 CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,  
 CC cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,  
 CC antianaemic, anorectic, antifertility, haemostatic, dermatological and  
 CC neuroprotective activities. (I) can be used as a therapeutic or  
 CC prophylactic agent as well as for screening purposes. (I) is useful for  
 CC diagnosing diseases characterised by dysfunction of their associated  
 CC protein of interest, for identifying normal or abnormal proteins of  
 CC interest, as a part of diagnostic kit to detect the presence of their  
 CC proteins of interest in a biological sample. Additionally, (I) is useful  
 CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,  
 CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,  
 CC infertility, and neurological degenerative diseases. (I), comprising  
 CC EPO-mimetic compounds are useful for treating disorders characterised by  
 CC low red blood cell levels such as anaemia. The TPO-mimetic comprising  
 CC compounds are useful for treating conditions that involve an existing  
 CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet

CC deficiency, such as thrombocytopenia, aplastic anaemia, metastatic  
 CC tumour which result in thrombocytopenia, systemic lupus erythematosus,  
 CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABB735695 to ABB735777  
 CC represent amino acid and nucleic acid sequences used in the  
 CC exemplification of the present invention.

SQ Sequence 10 AA;  
 Query Match 83.3%; Score 55; DB 23; Length 10;  
 Best Local Similarity 100.0%; Pred. No. 0.0052;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CATLRVYKGG 10  
 Db 1 CATLRVYKGG 10

RESULT 5  
 AAB17995  
 ID AAB17995 standard; Peptide; 9 AA.  
 XX AC AAB17995;  
 XX DT 31-OCT-2000 (first entry)  
 XX DE Membrane-transporting peptide sequence SEQ ID NO:1107.  
 XX KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;  
 KW autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;  
 KW immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;  
 KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;  
 KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;  
 KW vascular endothelial growth factor; matrix metalloproteinase;  
 KW asthma; thrombosis; pharmaceutical.  
 XX OS Synthetic.  
 XX WO200024782-A2.  
 XX PN 04-MAY-2000.  
 XX PD 25-OCT-1999; 99WO-US25044.  
 XX PF 23-OCT-1998; 98US-0105371.  
 XX PR 22-OCT-1999; 99US-0428082.  
 XX PA (AMGE-) AMGEN INC.  
 XX PI Feige U, Liu C, Cheetham J, Boone TC;  
 XX PI WPI; 2000-350702/30.  
 XX DR Novel composition of matter comprising an Fc domain and  
 XX PT pharmacologically active peptides, useful for treating cancer and  
 XX PT autoimmune diseases -  
 XX PS Claim 39; Page 601; 608pp; English.  
 XX CC The present invention describes composition of matter (I) comprising an  
 CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:  
 CC (X1)-a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each  
 CC independently selected from -(L1)c-p1, -(L1)c-p1-(L2)d-p2,  
 CC -(L1)c-p1-(L2)d-p2-(L3)e-p3, or -(L1)c-p1-(L2)d-p2-(L3)e-p3-(L4)f-p4  
 CC where F1, P2, P3, and P4 = are each independently sequences of  
 CC pharmacologically active peptides; L1, L2, L3, and L4 = are each  
 CC independently linkers; and a, b, c, d, e, and f = are each independently  
 CC 0 or 1, provided that at least 1 of a and b is 1. The composition can  
 CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive  
 CC activities. DNAs, vectors and host cells from the present invention can  
 CC be used for producing pharmaceutical compositions. The compositions are  
 CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.  
 CC The use of an Fc domain (rather than a Fab domain) can provide a longer  
 CC half-life or incorporate functions such as Fc receptor binding, protein

CC A binding, complement fixation, and possibly placental transfer. AA669443  
 CC to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid  
 CC sequences used in the exemplification of the present invention.

XX Sequence 9 AA;

Query Match 69.7%; Score 46; DB 21; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 9.3e+05;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 ATLRVYKGG 10  
 |||||  
 Db 1 ATLRVYKGG 9

RESULT 6

ABB73366  
 ID ABB73366 standard; Peptide; 9 AA.

XX AC ABB73366;

XX 05-APR-2002 (first entry)

XX Exemplary pharmacologically active peptide SEQ ID NO:1105.

XX Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;  
 KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;  
 KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TNP;  
 KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;  
 KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;  
 KW cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;  
 KW antianemic; anorectic; antinfertility; haemostatic; dermatological;  
 KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;  
 KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;  
 KW sleep disorder; neurological degenerative disease; anaemia;  
 KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;  
 KW Fanconi's syndrome.

XX Synthetic.

XX WO200183525-A2.

XX 08-NOV-2001.

XX 02-MAY-2001; 2001WO-US14310.

XX 03-MAY-2000; 2000US-0563286.

XX (AMGE-) AMGEN INC.

XX Feige U, Liu C, Cheestham JC, Boone TC, Gudas JM;

XX WPI; 2002-130313/17.

XX Novel vehicle-peptide molecule or its multimers useful for treating  
 PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,  
 PT diabetic retinopathy, obesity, sleep disorders and infertility

XX Claim 39; Page 62; 176pp; English.

XX The present invention describes a vehicle-peptide molecule (I) or its  
 CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,  
 CC cytotostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,  
 CC antianemic, anorectic, antinfertility, haemostatic, dermatological and  
 CC neuroprotective activities. (I) can be used as a therapeutic or  
 CC prophylactic agent as well as for screening purposes. (I) is useful for  
 CC diagnosing diseases characterised by dysfunction of their associated  
 CC protein of interest, for identifying normal or abnormal proteins of  
 CC interest, as a part of diagnostic kit to detect the presence of their  
 CC proteins of interest in a biological sample. Additionally, (I) is useful  
 CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,  
 CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,  
 CC infertility, and neurological degenerative diseases. (I), comprising

CC EPO-mimetic compounds are useful for treating disorders characterised by  
 CC low red blood cell levels such as anaemia. The TPO-mimetic comprising  
 CC compounds are useful for treating conditions that involve an existing  
 CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet  
 CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic  
 CC tumour which result in thrombocytopaenia, systemic lupus erythematosus,  
 CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777  
 CC represent amino acid and nucleic acid sequences used in the  
 CC exemplification of the present invention.

XX Sequence 9 AA;

Query Match 69.7%; Score 46; DB 23; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 9.3e+05;  
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 ATLRVYKGG 10  
 |||||  
 Db 1 ATLRVYKGG 9

RESULT 7

AAU46530

ID AAU46530 standard; Protein; 112 AA.

XX AC AAU46530;

XX 27-FEB-2002 (first entry)

XX Propionibacterium acnes immunogenic protein #7426.

XX SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;  
 KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;  
 KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;  
 KW dermatological; osteopathic; neuroprotectant.

XX Propionibacterium acnes.

XX WO200181581-A2.

XX 01-NOV-2001.

XX 20-APR-2001; 2001WO-US12865.

XX 21-APR-2000; 2000US-199047P.

XX 02-JUN-2000; 2000US-208841P.

XX 07-JUL-2000; 2000US-216747P.

XX (CORI-) CORIXA CORP.

XX Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;

XX L'maisonneuve J, Zhang Y, Jen S, Carter D;

XX WPI; 2001-616774/71.

XX N-PSDB; AAS9534.

XX Propionibacterium acnes polypeptides and nucleic acids useful for  
 PT vaccinating against and diagnosing infections, especially useful for  
 PT treating acne vulgaris

XX Example 1; SEQ ID No 7725; 1069pp; English.

XX Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic  
 CC polypeptides. The proteins and their associated DNA sequences are used in  
 CC the treatment, prevention and diagnosis of medical conditions caused by  
 CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,  
 CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.  
 CC P. acnes is also involved in infections of bone, joints and the central  
 CC nervous system, however it is particularly involved in the inflammatory  
 CC lesions associated with acne vulgaris. A method for detecting the  
 CC presence or absence of P. acnes in a patient comprises contacting a  
 CC sample with a binding agent that binds to the proteins of the invention  
 CC and determining the amount of bound protein in the sample. The

CC polypeptides may be used as antigens in the production of antibodies  
 CC specific for P. acnes proteins. These antibodies can be used to  
 CC downregulate expression and activity of P. acnes polypeptides and  
 CC therefore treat P. acnes infections. The antibodies may also be used as  
 CC diagnostic agents for determining P. acnes presence, for example, by  
 CC enzyme linked immunosorbent assay (ELISA).  
 CC Note: The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences.

XX Sequence 112 AA;

Query Match 57.6%; Score 38; DB 22; Length 112;

Best Local Similarity 63.6%; Pred. No. 58;

Matches 7; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1 CATLRVYKGGG 11

Db 37 CSTLRVYPTG 47

# RESULT 8

AG07912  
 ID ARG07912 standard; Protein: 266 AA.

XX AAG07912;

XX 17-OCT-2000 (first entry)

XX Arabidopsis thaliana protein fragment SEQ ID NO: 5244.

DE Protein identification; signal transduction pathway; metabolic pathway;  
 KW hybridisation assay; genetic mapping; gene expression control; promoter;  
 FW termination sequence.

XX Arabidopsis thaliana.

XX EP1033405-A2.

PD 06-SEP-2000.

XX 25-FEB-2000; 2000EP-0301439.

XX 25-FEB-1999; 99US-0121825.

PR 05-MAR-1999; 99US-0123180.

PR 09-MAR-1999; 99US-0123548.

PR 23-MAR-1999; 99US-0125788.

PR 25-MAR-1999; 99US-0126264.

PR 29-MAR-1999; 99US-0126785.

PR 01-APR-1999; 99US-0127462.

PR 06-APR-1999; 99US-0128234.

PR 08-APR-1999; 99US-0128714.

PR 16-APR-1999; 99US-0129845.

PR 19-APR-1999; 99US-0130077.

PR 21-APR-1999; 99US-0130449.

PR 23-APR-1999; 99US-0130510.

PR 23-APR-1999; 99US-0130891.

PR 28-APR-1999; 99US-0131449.

PR 30-APR-1999; 99US-0132048.

PR 30-APR-1999; 99US-0132407.

PR 04-MAY-1999; 99US-0132484.

PR 05-MAY-1999; 99US-0132485.

PR 06-MAY-1999; 99US-0132486.

PR 06-MAY-1999; 99US-0132487.

PR 07-MAY-1999; 99US-0132863.

PR 11-MAY-1999; 99US-0134256.

PR 14-MAY-1999; 99US-0134218.

PR 14-MAY-1999; 99US-0134219.

PR 14-MAY-1999; 99US-0134221.

PR 14-MAY-1999; 99US-0134370.

PR 18-MAY-1999; 99US-0134768.

PR 19-MAY-1999; 99US-0134941.

PR 20-MAY-1999; 99US-0135124.

PR 21-MAY-1999; 99US-0135353.  
 PR 24-MAY-1999; 99US-0135629.  
 PR 25-MAY-1999; 99US-0136021.  
 PR 27-MAY-1999; 99US-0136392.  
 PR 28-MAY-1999; 99US-0136782.  
 PR 01-JUN-1999; 99US-0137222.  
 PR 03-JUN-1999; 99US-0137528.  
 PR 04-JUN-1999; 99US-0137502.  
 PR 07-JUN-1999; 99US-0137724.  
 PR 08-JUN-1999; 99US-0138094.  
 PR 10-JUN-1999; 99US-0138540.  
 PR 10-JUN-1999; 99US-0138847.  
 PR 14-JUN-1999; 99US-0139119.  
 PR 16-JUN-1999; 99US-0139452.  
 PR 16-JUN-1999; 99US-0139453.  
 PR 17-JUN-1999; 99US-0139492.  
 PR 18-JUN-1999; 99US-0139454.  
 PR 18-JUN-1999; 99US-0139455.  
 PR 18-JUN-1999; 99US-0139456.  
 PR 18-JUN-1999; 99US-0139457.  
 PR 18-JUN-1999; 99US-0139458.  
 PR 18-JUN-1999; 99US-0139459.  
 PR 18-JUN-1999; 99US-0139460.  
 PR 18-JUN-1999; 99US-0139461.  
 PR 18-JUN-1999; 99US-0139462.  
 PR 18-JUN-1999; 99US-0139463.  
 PR 18-JUN-1999; 99US-0139750.  
 PR 18-JUN-1999; 99US-0139763.  
 PR 21-JUN-1999; 99US-0139817.  
 PR 22-JUN-1999; 99US-0139899.  
 PR 23-JUN-1999; 99US-0140353.  
 PR 24-JUN-1999; 99US-0140354.  
 PR 24-JUN-1999; 99US-0140695.  
 PR 28-JUN-1999; 99US-0140823.  
 PR 29-JUN-1999; 99US-0140981.  
 PR 30-JUN-1999; 99US-0141287.  
 PR 01-JUL-1999; 99US-0141842.  
 PR 01-JUL-1999; 99US-0142154.  
 PR 02-JUL-1999; 99US-0142055.  
 PR 06-JUL-1999; 99US-0142390.  
 PR 08-JUL-1999; 99US-0142803.  
 PR 09-JUL-1999; 99US-0142920.  
 PR 12-JUL-1999; 99US-0142977.  
 PR 13-JUL-1999; 99US-0143542.  
 PR 14-JUL-1999; 99US-0143624.  
 PR 15-JUL-1999; 99US-0144005.  
 PR 16-JUL-1999; 99US-0144085.  
 PR 16-JUL-1999; 99US-0144086.  
 PR 19-JUL-1999; 99US-0144325.  
 PR 19-JUL-1999; 99US-0144331.  
 PR 19-JUL-1999; 99US-0144332.  
 PR 19-JUL-1999; 99US-0144333.  
 PR 19-JUL-1999; 99US-0144334.  
 PR 19-JUL-1999; 99US-0144335.  
 PR 19-JUL-1999; 99US-0144352.  
 PR 20-JUL-1999; 99US-0144632.  
 PR 20-JUL-1999; 99US-0144884.  
 PR 21-JUL-1999; 99US-0144814.  
 PR 21-JUL-1999; 99US-0145086.  
 PR 21-JUL-1999; 99US-0145088.  
 PR 22-JUL-1999; 99US-0145085.  
 PR 22-JUL-1999; 99US-0145087.  
 PR 22-JUL-1999; 99US-0145089.  
 PR 22-JUL-1999; 99US-0145192.  
 PR 23-JUL-1999; 99US-0145145.  
 PR 23-JUL-1999; 99US-0145218.  
 PR 23-JUL-1999; 99US-0145224.  
 PR 26-JUL-1999; 99US-0145276.  
 PR 27-JUL-1999; 99US-0145913.  
 PR 27-JUL-1999; 99US-0145918.  
 PR 27-JUL-1999; 99US-0145919.  
 PR 28-JUL-1999; 99US-0145951.  
 PR 02-AUG-1999; 99US-0146386.

PR 02-AUG-1999; 99US-0146388.  
PR 02-AUG-1999; 99US-0146389.  
PR 03-AUG-1999; 99US-0147038.  
PR 04-AUG-1999; 99US-0147204.  
PR 04-AUG-1999; 99US-0147302.  
PR 05-AUG-1999; 99US-0147192.  
PR 05-AUG-1999; 99US-0147260.  
PR 06-AUG-1999; 99US-0147303.  
PR 06-AUG-1999; 99US-0147416.  
PR 09-AUG-1999; 99US-0147493.  
PR 09-AUG-1999; 99US-0147935.  
PR 10-AUG-1999; 99US-0148171.  
PR 11-AUG-1999; 99US-0148319.  
PR 12-AUG-1999; 99US-0148341.  
PR 13-AUG-1999; 99US-0148565.  
PR 13-AUG-1999; 99US-0148684.  
PR 16-AUG-1999; 99US-0149368.  
PR 17-AUG-1999; 99US-0149175.  
PR 18-AUG-1999; 99US-0149426.  
PR 20-AUG-1999; 99US-0149722.  
PR 20-AUG-1999; 99US-0149723.  
PR 20-AUG-1999; 99US-0149929.  
PR 23-AUG-1999; 99US-0149902.  
PR 23-AUG-1999; 99US-0149930.  
PR 25-AUG-1999; 99US-0150566.  
PR 25-AUG-1999; 99US-0150884.  
PR 27-AUG-1999; 99US-0151065.  
PR 27-AUG-1999; 99US-0151066.  
PR 27-AUG-1999; 99US-0151080.  
PR 30-AUG-1999; 99US-0151303.  
PR 31-AUG-1999; 99US-0151438.  
PR 01-SEP-1999; 99US-0151930.  
PR 07-SEP-1999; 99US-0152363.  
PR 10-SEP-1999; 99US-0153070.  
PR 13-SEP-1999; 99US-0153758.  
PR 15-SEP-1999; 99US-0154018.  
PR 16-SEP-1999; 99US-0154039.  
PR 20-SEP-1999; 99US-0154779.  
PR 22-SEP-1999; 99US-0155139.  
PR 23-SEP-1999; 99US-0155486.  
PR 24-SEP-1999; 99US-0155659.  
PR 28-SEP-1999; 99US-0156458.  
PR 28-SEP-1999; 99US-0156596.  
PR 04-OCT-1999; 99US-0157117.  
PR 05-OCT-1999; 99US-0157753.  
PR 06-OCT-1999; 99US-0157865.  
PR 07-OCT-1999; 99US-0158029.  
PR 08-OCT-1999; 99US-0158232.  
PR 12-OCT-1999; 99US-0158369.  
PR 13-OCT-1999; 99US-0159293.  
PR 13-OCT-1999; 99US-0159294.  
PR 13-OCT-1999; 99US-0159295.  
PR 14-OCT-1999; 99US-0159329.  
PR 14-OCT-1999; 99US-0159330.  
PR 14-OCT-1999; 99US-0159331.  
PR 14-OCT-1999; 99US-0159637.  
PR 14-OCT-1999; 99US-0159638.  
PR 18-OCT-1999; 99US-0159584.  
PR 21-OCT-1999; 99US-0160741.  
PR 21-OCT-1999; 99US-0160767.  
PR 21-OCT-1999; 99US-0160768.  
PR 21-OCT-1999; 99US-0160770.  
PR 21-OCT-1999; 99US-0160814.  
PR 21-OCT-1999; 99US-0160815.  
PR 22-OCT-1999; 99US-0160980.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160989.  
PR 25-OCT-1999; 99US-0161404.  
PR 25-OCT-1999; 99US-0161405.  
PR 25-OCT-1999; 99US-0161406.  
PR 26-OCT-1999; 99US-0161359.  
PR 26-OCT-1999; 99US-0161360.  
PR 26-OCT-1999; 99US-0161361.  
PR 28-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161992.  
PR 28-OCT-1999; 99US-0161993.  
PR 29-OCT-1999; 99US-0162142.  
Query Match 57.6%; Score 38; DB 21; Length 266;  
Best Local Similarity 53.8%; Pred. No. 1.5e+02;  
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;  
QY 1 CATLRVYKGGXA 13  
Db 114 CAFLSIQVGGAA 126  
RESULT 9  
AAG43155  
ID AAG43155 standard; Protein; 266 AA.  
XX AC AAG43155;  
XX DT 18-OCT-2000 (first entry)  
XX DE Arabidopsis thaliana protein fragment SEQ ID NO: 53906.  
XX KW Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
XX KW termination sequence.  
XX OS Arabidopsis thaliana.  
XX PN EP1033405-A2.  
XX PD 06-SEP-2000.  
XX PF 25-FEB-2000; 2000EP-0301439.  
XX PR 25-FEB-1999; 99US-0121825.  
PR 05-MAR-1999; 99US-0123180.  
PR 09-MAR-1999; 99US-0123548.  
PR 23-MAR-1999; 99US-0125788.  
PR 25-MAR-1999; 99US-0126264.  
PR 29-MAR-1999; 99US-0126785.  
PR 01-APR-1999; 99US-0127462.  
PR 06-APR-1999; 99US-0128234.  
PR 08-APR-1999; 99US-0128714.  
PR 16-APR-1999; 99US-0129845.  
PR 19-APR-1999; 99US-0130077.  
PR 21-APR-1999; 99US-0130449.  
PR 23-APR-1999; 99US-0130510.  
PR 23-APR-1999; 99US-0130891.  
PR 28-APR-1999; 99US-0131449.  
PR 30-APR-1999; 99US-0132048.  
PR 04-MAY-1999; 99US-0132407.  
PR 05-MAY-1999; 99US-0132484.  
PR 06-MAY-1999; 99US-0132485.  
PR 07-MAY-1999; 99US-0132487.  
PR 11-MAY-1999; 99US-0132863.  
PR 14-MAY-1999; 99US-0134256.  
PR 14-MAY-1999; 99US-0134218.  
PR 14-MAY-1999; 99US-0134219.  
PR 14-MAY-1999; 99US-0134221.  
PR 14-MAY-1999; 99US-0134370.  
PR 18-MAY-1999; 99US-0134768.  
PR 19-MAY-1999; 99US-0134941.  
PR 20-MAY-1999; 99US-0135124.  
PR 21-MAY-1999; 99US-0135353.  
PR 24-MAY-1999; 99US-0135629.  
PR 25-MAY-1999; 99US-0136021.  
PR 27-MAY-1999; 99US-0136392.  
PR 28-MAY-1999; 99US-0136782.  
PR 01-JUN-1999; 99US-0137222.  
PR 03-JUN-1999; 99US-0137528.

PR 04-JUN-1999; 99US-0137502.  
 PR 07-JUN-1999; 99US-0137724.  
 PR 08-JUN-1999; 99US-0138094.  
 PR 10-JUN-1999; 99US-0138540.  
 PR 14-JUN-1999; 99US-0138847.  
 PR 16-JUN-1999; 99US-0139119.  
 PR 16-JUN-1999; 99US-0139452.  
 PR 16-JUN-1999; 99US-0139453.  
 PR 17-JUN-1999; 99US-0139452.  
 PR 18-JUN-1999; 99US-0139454.  
 PR 18-JUN-1999; 99US-0139455.  
 PR 18-JUN-1999; 99US-0139456.  
 PR 18-JUN-1999; 99US-0139457.  
 PR 18-JUN-1999; 99US-0139458.  
 PR 18-JUN-1999; 99US-0139459.  
 PR 18-JUN-1999; 99US-0139460.  
 PR 18-JUN-1999; 99US-0139461.  
 PR 18-JUN-1999; 99US-0139462.  
 PR 18-JUN-1999; 99US-0139463.  
 PR 18-JUN-1999; 99US-0139750.  
 PR 18-JUN-1999; 99US-0139750.  
 PR 21-JUN-1999; 99US-0139817.  
 PR 22-JUN-1999; 99US-0139899.  
 PR 23-JUN-1999; 99US-0140353.  
 PR 23-JUN-1999; 99US-0140354.  
 PR 24-JUN-1999; 99US-0140695.  
 PR 28-JUN-1999; 99US-0140823.  
 PR 29-JUN-1999; 99US-0140991.  
 PR 30-JUN-1999; 99US-0141287.  
 PR 01-JUL-1999; 99US-0141842.  
 PR 01-JUL-1999; 99US-0142154.  
 PR 02-JUL-1999; 99US-0142055.  
 PR 06-JUL-1999; 99US-0142390.  
 PR 08-JUL-1999; 99US-0142803.  
 PR 09-JUL-1999; 99US-0142920.  
 PR 12-JUL-1999; 99US-0142977.  
 PR 13-JUL-1999; 99US-0143542.  
 PR 14-JUL-1999; 99US-0143624.  
 PR 15-JUL-1999; 99US-0144005.  
 PR 16-JUL-1999; 99US-0144085.  
 PR 16-JUL-1999; 99US-0144086.  
 PR 19-JUL-1999; 99US-0144325.  
 PR 19-JUL-1999; 99US-0144331.  
 PR 19-JUL-1999; 99US-0144332.  
 PR 19-JUL-1999; 99US-0144333.  
 PR 19-JUL-1999; 99US-0144334.  
 PR 19-JUL-1999; 99US-0144335.  
 PR 20-JUL-1999; 99US-0144632.  
 PR 20-JUL-1999; 99US-0144632.  
 PR 20-JUL-1999; 99US-0144684.  
 PR 21-JUL-1999; 99US-0144814.  
 PR 21-JUL-1999; 99US-0145086.  
 PR 21-JUL-1999; 99US-0145088.  
 PR 22-JUL-1999; 99US-0145087.  
 PR 22-JUL-1999; 99US-0145087.  
 PR 22-JUL-1999; 99US-0145089.  
 PR 22-JUL-1999; 99US-0145192.  
 PR 23-JUL-1999; 99US-0145145.  
 PR 23-JUL-1999; 99US-0145218.  
 PR 23-JUL-1999; 99US-0145224.  
 PR 26-JUL-1999; 99US-0145276.  
 PR 27-JUL-1999; 99US-0145913.  
 PR 27-JUL-1999; 99US-0145918.  
 PR 27-JUL-1999; 99US-0145919.  
 PR 28-JUL-1999; 99US-0145951.  
 PR 02-AUG-1999; 99US-0146386.  
 PR 02-AUG-1999; 99US-0146388.  
 PR 02-AUG-1999; 99US-0146389.  
 PR 03-AUG-1999; 99US-0147038.  
 PR 04-AUG-1999; 99US-0147204.  
 PR 04-AUG-1999; 99US-0147302.  
 PR 05-AUG-1999; 99US-0147192.  
 PR 05-AUG-1999; 99US-0147260.

PR 06-AUG-1999; 99US-0147303.  
 PR 06-AUG-1999; 99US-0147416.  
 PR 09-AUG-1999; 99US-0147493.  
 PR 09-AUG-1999; 99US-0147935.  
 PR 10-AUG-1999; 99US-0148171.  
 PR 11-AUG-1999; 99US-0148319.  
 PR 12-AUG-1999; 99US-0148341.  
 PR 13-AUG-1999; 99US-0148565.  
 PR 13-AUG-1999; 99US-0148684.  
 PR 16-AUG-1999; 99US-0149368.  
 PR 17-AUG-1999; 99US-0149175.  
 PR 18-AUG-1999; 99US-0149426.  
 PR 20-AUG-1999; 99US-0149722.  
 PR 20-AUG-1999; 99US-0149723.  
 PR 20-AUG-1999; 99US-0149929.  
 PR 23-AUG-1999; 99US-0149902.  
 PR 23-AUG-1999; 99US-0149930.  
 PR 25-AUG-1999; 99US-0150566.  
 PR 26-AUG-1999; 99US-0150884.  
 PR 27-AUG-1999; 99US-0151065.  
 PR 27-AUG-1999; 99US-0151066.  
 PR 27-AUG-1999; 99US-0151080.  
 PR 30-AUG-1999; 99US-0151303.  
 PR 31-AUG-1999; 99US-0151438.  
 PR 01-SEP-1999; 99US-0151930.  
 PR 07-SEP-1999; 99US-0152363.  
 PR 10-SEP-1999; 99US-0153070.  
 PR 13-SEP-1999; 99US-0153758.  
 PR 13-SEP-1999; 99US-0154018.  
 PR 16-SEP-1999; 99US-0154039.  
 PR 20-SEP-1999; 99US-0154779.  
 PR 22-SEP-1999; 99US-0155139.  
 PR 23-SEP-1999; 99US-0155486.  
 PR 24-SEP-1999; 99US-0155659.  
 PR 28-SEP-1999; 99US-0156458.  
 PR 29-SEP-1999; 99US-0156596.  
 PR 04-OCT-1999; 99US-0157117.  
 PR 05-OCT-1999; 99US-0157753.  
 PR 06-OCT-1999; 99US-0157865.  
 PR 07-OCT-1999; 99US-0158029.  
 PR 08-OCT-1999; 99US-0158232.  
 PR 12-OCT-1999; 99US-0158369.  
 PR 13-OCT-1999; 99US-0159293.  
 PR 13-OCT-1999; 99US-0159294.  
 PR 13-OCT-1999; 99US-0159295.  
 PR 14-OCT-1999; 99US-0159330.  
 PR 14-OCT-1999; 99US-0159331.  
 PR 14-OCT-1999; 99US-0159637.  
 PR 14-OCT-1999; 99US-0159638.  
 PR 18-OCT-1999; 99US-0159584.  
 PR 21-OCT-1999; 99US-0160741.  
 PR 21-OCT-1999; 99US-0160767.  
 PR 21-OCT-1999; 99US-0160768.  
 PR 21-OCT-1999; 99US-0160770.  
 PR 21-OCT-1999; 99US-0160814.  
 PR 21-OCT-1999; 99US-0160815.  
 PR 22-OCT-1999; 99US-0160980.  
 PR 22-OCT-1999; 99US-0160981.  
 PR 22-OCT-1999; 99US-0160989.  
 PR 25-OCT-1999; 99US-0161404.  
 PR 25-OCT-1999; 99US-0161405.  
 PR 25-OCT-1999; 99US-0161406.  
 PR 26-OCT-1999; 99US-0161359.  
 PR 26-OCT-1999; 99US-0161360.  
 PR 26-OCT-1999; 99US-0161361.  
 PR 28-OCT-1999; 99US-0161920.  
 PR 28-OCT-1999; 99US-0161992.  
 PR 28-OCT-1999; 99US-0161993.  
 PR 29-OCT-1999; 99US-0162142.

Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

OY 1 CATLRVYKGGXA 13  
Db 114 CAFLSIYQVGGAA 126

RESULT 10  
AAG07911  
ID AAG07911 standard; Protein; 283 AA.  
AC AAG07911;  
XX  
XX  
DT 17-OCT-2000 (first entry)  
XX  
DE Arabidopsis thaliana protein fragment SEQ ID NO: 5243.  
XX  
KW Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence.  
XX  
OS Arabidopsis thaliana.  
XX  
PN EP1033405-A2.  
XX  
PD 06-SEP-2000.  
XX  
XX 25-FEB-2000; 2000EP-0301439.  
XX  
XX 25-FEB-1999; 99US-0121825.  
PR 05-MAR-1999; 99US-0123180.  
PR 09-MAR-1999; 99US-0123548.  
PR 23-MAR-1999; 99US-0125788.  
PR 25-MAR-1999; 99US-0126264.  
PR 23-MAR-1999; 99US-0126785.  
PR 01-APR-1999; 99US-0127462.  
PR 06-APR-1999; 99US-0128234.  
PR 08-APR-1999; 99US-0128714.  
PR 16-APR-1999; 99US-0129845.  
PR 19-APR-1999; 99US-0130077.  
PR 21-APR-1999; 99US-0130449.  
PR 23-APR-1999; 99US-0130510.  
PR 23-APR-1999; 99US-0130891.  
PR 28-APR-1999; 99US-0131449.  
PR 30-APR-1999; 99US-0132048.  
PR 30-APR-1999; 99US-0132407.  
PR 04-MAY-1999; 99US-0132484.  
PR 05-MAY-1999; 99US-0132485.  
PR 06-MAY-1999; 99US-0132486.  
PR 07-MAY-1999; 99US-0132487.  
PR 11-MAY-1999; 99US-0132563.  
PR 14-MAY-1999; 99US-0134218.  
PR 14-MAY-1999; 99US-0134219.  
PR 14-MAY-1999; 99US-0134221.  
PR 18-MAY-1999; 99US-0134370.  
PR 18-MAY-1999; 99US-0134768.  
PR 19-MAY-1999; 99US-0134941.  
PR 20-MAY-1999; 99US-0135124.  
PR 21-MAY-1999; 99US-0135353.  
PR 24-MAY-1999; 99US-0135629.  
PR 25-MAY-1999; 99US-0136021.  
PR 27-MAY-1999; 99US-0136392.  
PR 28-MAY-1999; 99US-0136782.  
PR 01-JUN-1999; 99US-0137222.  
PR 03-JUN-1999; 99US-0137528.  
PR 04-JUN-1999; 99US-0137502.  
PR 07-JUN-1999; 99US-0137724.  
PR 08-JUN-1999; 99US-0138094.  
PR 10-JUN-1999; 99US-0138540.  
PR 10-JUN-1999; 99US-0138847.  
PR 14-JUN-1999; 99US-0139119.  
PR 16-JUN-1999; 99US-0139452.  
PR 16-JUN-1999; 99US-0139453.  
PR 17-JUN-1999; 99US-0139492.  
PR 18-JUN-1999; 99US-0139454.  
PR 18-JUN-1999; 99US-0139455.  
PR 18-JUN-1999; 99US-0139456.  
PR 18-JUN-1999; 99US-0139457.  
PR 18-JUN-1999; 99US-0139458.  
PR 18-JUN-1999; 99US-0139459.  
PR 18-JUN-1999; 99US-0139460.  
PR 18-JUN-1999; 99US-0139461.  
PR 18-JUN-1999; 99US-0139462.  
PR 18-JUN-1999; 99US-0139463.  
PR 18-JUN-1999; 99US-0139750.  
PR 18-JUN-1999; 99US-0139763.  
PR 21-JUN-1999; 99US-0139817.  
PR 22-JUN-1999; 99US-0139899.  
PR 23-JUN-1999; 99US-0140353.  
PR 23-JUN-1999; 99US-0140354.  
PR 24-JUN-1999; 99US-0140695.  
PR 28-JUN-1999; 99US-0140823.  
PR 29-JUN-1999; 99US-0140991.  
PR 30-JUN-1999; 99US-0141287.  
PR 01-JUL-1999; 99US-0141842.  
PR 01-JUL-1999; 99US-0142154.  
PR 02-JUL-1999; 99US-0142055.  
PR 06-JUL-1999; 99US-0142390.  
PR 08-JUL-1999; 99US-0142803.  
PR 09-JUL-1999; 99US-0142920.  
PR 12-JUL-1999; 99US-0142977.  
PR 13-JUL-1999; 99US-0143542.  
PR 14-JUL-1999; 99US-0143624.  
PR 15-JUL-1999; 99US-0144005.  
PR 16-JUL-1999; 99US-0144085.  
PR 16-JUL-1999; 99US-0144086.  
PR 19-JUL-1999; 99US-0144325.  
PR 19-JUL-1999; 99US-0144331.  
PR 19-JUL-1999; 99US-0144332.  
PR 19-JUL-1999; 99US-0144333.  
PR 19-JUL-1999; 99US-0144334.  
PR 19-JUL-1999; 99US-0144335.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144632.  
PR 21-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0145086.  
PR 21-JUL-1999; 99US-0145088.  
PR 22-JUL-1999; 99US-0145085.  
PR 22-JUL-1999; 99US-0145087.  
PR 22-JUL-1999; 99US-0145089.  
PR 22-JUL-1999; 99US-0145192.  
PR 23-JUL-1999; 99US-0145145.  
PR 23-JUL-1999; 99US-0145218.  
PR 23-JUL-1999; 99US-0145224.  
PR 26-JUL-1999; 99US-0145276.  
PR 27-JUL-1999; 99US-0145913.  
PR 27-JUL-1999; 99US-0145918.  
PR 27-JUL-1999; 99US-0145919.  
PR 28-JUL-1999; 99US-0145951.  
PR 02-AUG-1999; 99US-0146386.  
PR 02-AUG-1999; 99US-0146388.  
PR 02-AUG-1999; 99US-0146389.  
PR 03-AUG-1999; 99US-0147038.  
PR 04-AUG-1999; 99US-0147204.  
PR 04-AUG-1999; 99US-0147302.  
PR 05-AUG-1999; 99US-0147192.  
PR 05-AUG-1999; 99US-0147260.  
PR 06-AUG-1999; 99US-0147303.  
PR 06-AUG-1999; 99US-0147416.  
PR 09-AUG-1999; 99US-0147493.  
PR 09-AUG-1999; 99US-0147935.  
PR 10-AUG-1999; 99US-0148171.  
PR 11-AUG-1999; 99US-0148319.  
PR 12-AUG-1999; 99US-0148341.

```
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 27-AUG-1999; 99US-0151303.
PR 30-AUG-1999; 99US-0151438.
PR 31-AUG-1999; 99US-0151930.
PR 01-SEP-1999; 99US-0152363.
PR 07-SEP-1999; 99US-0153070.
PR 10-SEP-1999; 99US-0153758.
PR 13-SEP-1999; 99US-0154018.
PR 15-SEP-1999; 99US-0154039.
PR 16-SEP-1999; 99US-0154779.
PR 20-SEP-1999; 99US-0155139.
PR 22-SEP-1999; 99US-0155486.
PR 23-SEP-1999; 99US-0155659.
PR 24-SEP-1999; 99US-0156458.
PR 28-SEP-1999; 99US-0156596.
PR 29-SEP-1999; 99US-0157117.
PR 04-OCT-1999; 99US-0157753.
PR 05-OCT-1999; 99US-0157865.
PR 06-OCT-1999; 99US-0158029.
PR 07-OCT-1999; 99US-0158232.
PR 08-OCT-1999; 99US-0158369.
PR 12-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 57.6%; Score 38; DB 21; Length 283;
Best Local Similarity 53.8%; Pred. No. 1.6e+02;
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CATLRVYKGGXA 13
|||:::|
Db 131 CAFLSIQVGGAA 143
```

RESULT 11  
AAG43154  
ID AAG43154 standard; Protein; 283 AA.  
XX AAG43154;  
AC AAG43154;  
XX 18-OCT-2000 (first entry)  
DT 18-OCT-2000 (first entry)  
XX Arabidopsis thaliana protein fragment SEQ ID NO: 53905.  
DE Arabidopsis thaliana.  
XX Protein identification; signal transduction pathway; metabolic pathway;  
KW hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence.  
XX Arabidopsis thaliana.  
OS Arabidopsis thaliana.  
XX EPI033405-A2.  
PN 06-SEP-2000.  
PD 25-FEB-2000; 2000EP-0301439.  
PF 25-FEB-1999; 99US-0121825.  
XX 05-MAR-1999; 99US-0123180.  
PR 09-MAR-1999; 99US-0123548.  
PR 23-MAR-1999; 99US-0125788.  
PR 25-MAR-1999; 99US-0126264.  
PR 29-MAR-1999; 99US-0126785.  
PR 01-APR-1999; 99US-0127462.  
PR 06-APR-1999; 99US-0128234.  
PR 08-APR-1999; 99US-0128714.  
PR 16-APR-1999; 99US-0129845.  
PR 19-APR-1999; 99US-0130077.  
PR 21-APR-1999; 99US-0130449.  
PR 23-APR-1999; 99US-0130510.  
PR 23-APR-1999; 99US-0130891.  
PR 30-APR-1999; 99US-0131449.  
PR 30-APR-1999; 99US-0132048.  
PR 30-APR-1999; 99US-0132407.  
PR 04-MAY-1999; 99US-0132484.  
PR 05-MAY-1999; 99US-0132485.  
PR 06-MAY-1999; 99US-0132486.  
PR 06-MAY-1999; 99US-0132487.  
PR 07-MAY-1999; 99US-0132863.  
PR 11-MAY-1999; 99US-0134256.  
PR 14-MAY-1999; 99US-0134218.  
PR 14-MAY-1999; 99US-0134219.  
PR 14-MAY-1999; 99US-0134221.  
PR 14-MAY-1999; 99US-0134370.  
PR 18-MAY-1999; 99US-0134768.  
PR 19-MAY-1999; 99US-0134941.  
PR 20-MAY-1999; 99US-0135124.  
PR 21-MAY-1999; 99US-0135353.  
PR 25-MAY-1999; 99US-0135629.  
PR 25-MAY-1999; 99US-0136021.  
PR 27-MAY-1999; 99US-0136392.  
PR 28-MAY-1999; 99US-0136782.  
PR 01-JUN-1999; 99US-0137222.  
PR 03-JUN-1999; 99US-0137528.  
PR 04-JUN-1999; 99US-0137502.  
PR 07-JUN-1999; 99US-0137724.  
PR 08-JUN-1999; 99US-0138094.  
PR 10-JUN-1999; 99US-0138540.  
PR 10-JUN-1999; 99US-0138847.  
PR 14-JUN-1999; 99US-0139119.  
PR 16-JUN-1999; 99US-0139452.  
PR 16-JUN-1999; 99US-0139453.  
PR 17-JUN-1999; 99US-0139492.  
PR 18-JUN-1999; 99US-0139454.  
PR 18-JUN-1999; 99US-0139455.  
PR 18-JUN-1999; 99US-0139456.  
PR 18-JUN-1999; 99US-0139457.  
PR 18-JUN-1999; 99US-0139458.

PR 18-JUN-1999; 99US-0139459.  
PR 18-JUN-1999; 99US-0139460.  
PR 18-JUN-1999; 99US-0139461.  
PR 18-JUN-1999; 99US-0139462.  
PR 18-JUN-1999; 99US-0139463.  
PR 18-JUN-1999; 99US-0139750.  
PR 18-JUN-1999; 99US-0139763.  
PR 21-JUN-1999; 99US-0139817.  
PR 22-JUN-1999; 99US-0139899.  
PR 23-JUN-1999; 99US-0140353.  
PR 23-JUN-1999; 99US-0140354.  
PR 24-JUN-1999; 99US-0140895.  
PR 28-JUN-1999; 99US-0140823.  
PR 29-JUN-1999; 99US-0140991.  
PR 30-JUN-1999; 99US-0141287.  
PR 01-JUL-1999; 99US-0141842.  
PR 01-JUL-1999; 99US-0142154.  
PR 02-JUL-1999; 99US-0142055.  
PR 06-JUL-1999; 99US-0142390.  
PR 08-JUL-1999; 99US-0142803.  
PR 09-JUL-1999; 99US-0142920.  
PR 12-JUL-1999; 99US-0142977.  
PR 13-JUL-1999; 99US-0143542.  
PR 14-JUL-1999; 99US-0143624.  
PR 15-JUL-1999; 99US-0144005.  
PR 16-JUL-1999; 99US-0144085.  
PR 16-JUL-1999; 99US-0144086.  
PR 19-JUL-1999; 99US-0144325.  
PR 19-JUL-1999; 99US-0144331.  
PR 19-JUL-1999; 99US-0144332.  
PR 19-JUL-1999; 99US-0144333.  
PR 19-JUL-1999; 99US-0144334.  
PR 19-JUL-1999; 99US-0144335.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144352.  
PR 21-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0144814.  
PR 21-JUL-1999; 99US-0145086.  
PR 21-JUL-1999; 99US-0145088.  
PR 21-JUL-1999; 99US-0145085.  
PR 22-JUL-1999; 99US-0145087.  
PR 22-JUL-1999; 99US-0145089.  
PR 22-JUL-1999; 99US-0145192.  
PR 23-JUL-1999; 99US-0145192.  
PR 23-JUL-1999; 99US-0145145.  
PR 23-JUL-1999; 99US-0145218.  
PR 23-JUL-1999; 99US-0145224.  
PR 26-JUL-1999; 99US-0145276.  
PR 27-JUL-1999; 99US-0145913.  
PR 27-JUL-1999; 99US-0145918.  
PR 27-JUL-1999; 99US-0145919.  
PR 28-JUL-1999; 99US-0145951.  
PR 02-AUG-1999; 99US-0146386.  
PR 02-AUG-1999; 99US-0146388.  
PR 02-AUG-1999; 99US-0146389.  
PR 03-AUG-1999; 99US-0147038.  
PR 04-AUG-1999; 99US-0147302.  
PR 04-AUG-1999; 99US-0147302.  
PR 05-AUG-1999; 99US-0147192.  
PR 06-AUG-1999; 99US-0147260.  
PR 06-AUG-1999; 99US-0147303.  
PR 06-AUG-1999; 99US-0147416.  
PR 09-AUG-1999; 99US-0147493.  
PR 09-AUG-1999; 99US-0147935.  
PR 10-AUG-1999; 99US-0148171.  
PR 11-AUG-1999; 99US-0148319.  
PR 12-AUG-1999; 99US-0148341.  
PR 13-AUG-1999; 99US-0148565.  
PR 13-AUG-1999; 99US-0148684.  
PR 16-AUG-1999; 99US-0149368.  
PR 17-AUG-1999; 99US-0149175.  
PR 18-AUG-1999; 99US-0149426.  
PR 20-AUG-1999; 99US-0149722.  
PR 20-AUG-1999; 99US-0149723.

PR 20-AUG-1999; 99US-0149929.  
PR 23-AUG-1999; 99US-0149902.  
PR 23-AUG-1999; 99US-0149930.  
PR 25-AUG-1999; 99US-0150566.  
PR 26-AUG-1999; 99US-0150884.  
PR 27-AUG-1999; 99US-0151065.  
PR 27-AUG-1999; 99US-0151066.  
PR 27-AUG-1999; 99US-0151080.  
PR 30-AUG-1999; 99US-0151303.  
PR 31-AUG-1999; 99US-0151438.  
PR 01-SEP-1999; 99US-0151930.  
PR 07-SEP-1999; 99US-0152363.  
PR 10-SEP-1999; 99US-0153070.  
PR 13-SEP-1999; 99US-0153758.  
PR 15-SEP-1999; 99US-0154018.  
PR 16-SEP-1999; 99US-0154039.  
PR 20-SEP-1999; 99US-0154779.  
PR 22-SEP-1999; 99US-0155139.  
PR 23-SEP-1999; 99US-0155486.  
PR 24-SEP-1999; 99US-0155659.  
PR 28-SEP-1999; 99US-0156458.  
PR 29-SEP-1999; 99US-0156596.  
PR 04-OCT-1999; 99US-0157117.  
PR 05-OCT-1999; 99US-0157753.  
PR 06-OCT-1999; 99US-0157865.  
PR 07-OCT-1999; 99US-0158029.  
PR 08-OCT-1999; 99US-0158232.  
PR 12-OCT-1999; 99US-0158369.  
PR 13-OCT-1999; 99US-0159293.  
PR 13-OCT-1999; 99US-0159294.  
PR 13-OCT-1999; 99US-0159295.  
PR 14-OCT-1999; 99US-0159329.  
PR 14-OCT-1999; 99US-0159330.  
PR 14-OCT-1999; 99US-0159331.  
PR 14-OCT-1999; 99US-0159637.  
PR 14-OCT-1999; 99US-0159638.  
PR 18-OCT-1999; 99US-0159584.  
PR 21-OCT-1999; 99US-0160741.  
PR 21-OCT-1999; 99US-0160767.  
PR 21-OCT-1999; 99US-0160768.  
PR 21-OCT-1999; 99US-0160770.  
PR 21-OCT-1999; 99US-0160814.  
PR 21-OCT-1999; 99US-0160815.  
PR 22-OCT-1999; 99US-0160980.  
PR 22-OCT-1999; 99US-0160981.  
PR 22-OCT-1999; 99US-0160989.  
PR 25-OCT-1999; 99US-0161404.  
PR 25-OCT-1999; 99US-0161405.  
PR 25-OCT-1999; 99US-0161406.  
PR 26-OCT-1999; 99US-0161359.  
PR 26-OCT-1999; 99US-0161360.  
PR 26-OCT-1999; 99US-0161361.  
PR 26-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161920.  
PR 28-OCT-1999; 99US-0161992.  
PR 28-OCT-1999; 99US-0161993.  
PR 29-OCT-1999; 99US-0162142.

Query Match 57.6%; Score 38; DB 21; Length 283;  
Best Local Similarity 53.8%; Pred. NO. 1.6e+02;  
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CATLRVYKGGXA 13  
|||:|:|:  
Db 131 CAPLSIYQVGGA 143

RESULT 12  
AAG07910  
ID AAG07910 standard; Protein; 333 AA.  
XX  
AC AAG07910;  
XX  
DT 17-OCT-2000 (first entry)

XX Arabidopsis thaliana protein fragment SEQ ID NO: 5242.  
DE Protein identification; signal transduction pathway; metabolic pathway;  
XX hybridisation assay; genetic mapping; gene expression control; promoter;  
KW termination sequence.  
KW  
XX Arabidopsis thaliana.  
OS  
XX  
PN EP1033405-A2.  
PD  
XX 06-SEP-2000.  
PF  
XX 25-FEB-2000; 2000EP-0301439.  
XX  
PR 25-FEB-1999; 99US-0121825.  
PR 05-MAR-1999; 99US-0123180.  
PR 09-MAR-1999; 99US-0123548.  
PR 23-MAR-1999; 99US-0125788.  
PR 25-MAR-1999; 99US-0126264.  
PR 29-MAR-1999; 99US-0126785.  
PR 01-APR-1999; 99US-0127462.  
PR 06-APR-1999; 99US-0128234.  
PR 08-APR-1999; 99US-0128714.  
PR 16-APR-1999; 99US-0129845.  
PR 19-APR-1999; 99US-0130077.  
PR 21-APR-1999; 99US-0130449.  
PR 23-APR-1999; 99US-0130510.  
PR 23-APR-1999; 99US-0130891.  
PR 28-APR-1999; 99US-0131449.  
PR 30-APR-1999; 99US-0132048.  
PR 30-APR-1999; 99US-0132407.  
PR 04-MAY-1999; 99US-0132484.  
PR 05-MAY-1999; 99US-0132485.  
PR 06-MAY-1999; 99US-0132486.  
PR 06-MAY-1999; 99US-0132487.  
PR 07-MAY-1999; 99US-0132863.  
PR 11-MAY-1999; 99US-0134256.  
PR 14-MAY-1999; 99US-0134218.  
PR 14-MAY-1999; 99US-0134219.  
PR 14-MAY-1999; 99US-0134221.  
PR 14-MAY-1999; 99US-0134370.  
PR 18-MAY-1999; 99US-0134768.  
PR 19-MAY-1999; 99US-0134941.  
PR 20-MAY-1999; 99US-0135124.  
PR 21-MAY-1999; 99US-0135353.  
PR 24-MAY-1999; 99US-0135629.  
PR 25-MAY-1999; 99US-0136021.  
PR 27-MAY-1999; 99US-0136392.  
PR 28-MAY-1999; 99US-0136782.  
PR 01-JUN-1999; 99US-0137222.  
PR 03-JUN-1999; 99US-0137528.  
PR 04-JUN-1999; 99US-0137502.  
PR 07-JUN-1999; 99US-0137724.  
PR 08-JUN-1999; 99US-0138094.  
PR 10-JUN-1999; 99US-0138540.  
PR 10-JUN-1999; 99US-0138847.  
PR 14-JUN-1999; 99US-0139119.  
PR 16-JUN-1999; 99US-0139452.  
PR 16-JUN-1999; 99US-0139453.  
PR 17-JUN-1999; 99US-0139492.  
PR 18-JUN-1999; 99US-0139454.  
PR 18-JUN-1999; 99US-0139455.  
PR 18-JUN-1999; 99US-0139456.  
PR 18-JUN-1999; 99US-0139457.  
PR 18-JUN-1999; 99US-0139458.  
PR 18-JUN-1999; 99US-0139459.  
PR 18-JUN-1999; 99US-0139460.  
PR 18-JUN-1999; 99US-0139461.  
PR 18-JUN-1999; 99US-0139462.  
PR 18-JUN-1999; 99US-0139463.  
PR 18-JUN-1999; 99US-0139750.  
PR 18-JUN-1999; 99US-0139763.  
PR 21-JUN-1999; 99US-0139817.  
PR 22-JUN-1999; 99US-0139899.  
PR 23-JUN-1999; 99US-0140353.  
PR 23-JUN-1999; 99US-0140354.  
PR 24-JUN-1999; 99US-0140695.  
PR 28-JUN-1999; 99US-0140823.  
PR 29-JUN-1999; 99US-0140991.  
PR 30-JUN-1999; 99US-0141287.  
PR 01-JUL-1999; 99US-0141842.  
PR 02-JUL-1999; 99US-0142154.  
PR 02-JUL-1999; 99US-0142055.  
PR 06-JUL-1999; 99US-0142390.  
PR 08-JUL-1999; 99US-0142803.  
PR 09-JUL-1999; 99US-0142920.  
PR 12-JUL-1999; 99US-0142977.  
PR 13-JUL-1999; 99US-0143542.  
PR 14-JUL-1999; 99US-0143624.  
PR 15-JUL-1999; 99US-0144005.  
PR 16-JUL-1999; 99US-0144085.  
PR 16-JUL-1999; 99US-0144086.  
PR 19-JUL-1999; 99US-0144325.  
PR 19-JUL-1999; 99US-0144331.  
PR 19-JUL-1999; 99US-0144332.  
PR 19-JUL-1999; 99US-0144333.  
PR 19-JUL-1999; 99US-0144334.  
PR 19-JUL-1999; 99US-0144335.  
PR 20-JUL-1999; 99US-0144352.  
PR 20-JUL-1999; 99US-0144632.  
PR 20-JUL-1999; 99US-0144884.  
PR 21-JUL-1999; 99US-0144814.  
PR 21-JUL-1999; 99US-0145086.  
PR 21-JUL-1999; 99US-0145088.  
PR 22-JUL-1999; 99US-0145085.  
PR 22-JUL-1999; 99US-0145087.  
PR 22-JUL-1999; 99US-0145089.  
PR 22-JUL-1999; 99US-0145192.  
PR 23-JUL-1999; 99US-0145145.  
PR 23-JUL-1999; 99US-0145218.  
PR 23-JUL-1999; 99US-0145224.  
PR 26-JUL-1999; 99US-0145276.  
PR 27-JUL-1999; 99US-0145913.  
PR 27-JUL-1999; 99US-0145918.  
PR 27-JUL-1999; 99US-0145919.  
PR 28-JUL-1999; 99US-0145951.  
PR 02-AUG-1999; 99US-0146386.  
PR 02-AUG-1999; 99US-0146388.  
PR 02-AUG-1999; 99US-0146389.  
PR 03-AUG-1999; 99US-0147038.  
PR 04-AUG-1999; 99US-0147204.  
PR 04-AUG-1999; 99US-0147302.  
PR 05-AUG-1999; 99US-0147192.  
PR 05-AUG-1999; 99US-0147260.  
PR 06-AUG-1999; 99US-0147303.  
PR 06-AUG-1999; 99US-0147416.  
PR 09-AUG-1999; 99US-0147493.  
PR 09-AUG-1999; 99US-0147935.  
PR 10-AUG-1999; 99US-0148171.  
PR 11-AUG-1999; 99US-0148319.  
PR 12-AUG-1999; 99US-0148341.  
PR 13-AUG-1999; 99US-0148565.  
PR 13-AUG-1999; 99US-0148684.  
PR 16-AUG-1999; 99US-0149368.  
PR 17-AUG-1999; 99US-0149175.  
PR 18-AUG-1999; 99US-0149426.  
PR 20-AUG-1999; 99US-0149722.  
PR 20-AUG-1999; 99US-0149723.  
PR 20-AUG-1999; 99US-0149929.  
PR 23-AUG-1999; 99US-0149902.  
PR 23-AUG-1999; 99US-0149930.  
PR 25-AUG-1999; 99US-0150566.  
PR 26-AUG-1999; 99US-0150884.  
PR 27-AUG-1999; 99US-0151065.  
PR 27-AUG-1999; 99US-0151066.

```

PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159638.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 57.6%; Score 38; DB 21; Length 333.
Best Local Similarity 53.8%; Pred. No. 1.8e+02;
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CATLRYKGGGXA 13
Db 181 CAFLSIQVGAA 193
|||:|:|

RESULT 13
AAG43153
ID AAG43153 standard; Protein; 333 AA.
XX AC AAG43153;
XX DT 18-OCT-2000 (first entry)
XX DE Arabidopsis thaliana protein fragment SEQ ID NO: 53904.
XX KW Protein identification; signal transduction pathway; metabolic pathway;
XX KW hybridisation assay; genetic mapping; gene expression control; promoter;
XX KW termination sequence.

```

---

```

OS Arabidopsis thaliana.
XX PN EP1033405-A2.
XX PD 06-SEP-2000.
XX PF 25-FEB-2000; 2000EP-0301439.
XX PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 07-MAY-1999; 99US-0132487.
PR 11-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.

```

PR 30-JUN-1999; 99US-0141287.  
 PR 01-JUL-1999; 99US-0141842.  
 PR 01-JUL-1999; 99US-0142154.  
 PR 02-JUL-1999; 99US-0142055.  
 PR 06-JUL-1999; 99US-0142390.  
 PR 08-JUL-1999; 99US-0142803.  
 PR 09-JUL-1999; 99US-0142920.  
 PR 12-JUL-1999; 99US-0142977.  
 PR 13-JUL-1999; 99US-0143542.  
 PR 14-JUL-1999; 99US-0143624.  
 PR 15-JUL-1999; 99US-0144005.  
 PR 16-JUL-1999; 99US-0144085.  
 PR 16-JUL-1999; 99US-0144086.  
 PR 19-JUL-1999; 99US-0144325.  
 PR 19-JUL-1999; 99US-0144331.  
 PR 19-JUL-1999; 99US-0144332.  
 PR 19-JUL-1999; 99US-0144333.  
 PR 19-JUL-1999; 99US-0144334.  
 PR 19-JUL-1999; 99US-0144335.  
 PR 20-JUL-1999; 99US-0144352.  
 PR 20-JUL-1999; 99US-0144632.  
 PR 20-JUL-1999; 99US-0144884.  
 PR 21-JUL-1999; 99US-0144814.  
 PR 21-JUL-1999; 99US-0145086.  
 PR 21-JUL-1999; 99US-0145088.  
 PR 22-JUL-1999; 99US-0145085.  
 PR 22-JUL-1999; 99US-0145087.  
 PR 22-JUL-1999; 99US-0145089.  
 PR 22-JUL-1999; 99US-0145192.  
 PR 23-JUL-1999; 99US-0145145.  
 PR 23-JUL-1999; 99US-0145218.  
 PR 23-JUL-1999; 99US-0145224.  
 PR 26-JUL-1999; 99US-0145276.  
 PR 27-JUL-1999; 99US-0145913.  
 PR 27-JUL-1999; 99US-0145918.  
 PR 27-JUL-1999; 99US-0145919.  
 PR 28-JUL-1999; 99US-0145951.  
 PR 02-AUG-1999; 99US-0146386.  
 PR 02-AUG-1999; 99US-0146388.  
 PR 02-AUG-1999; 99US-0146389.  
 PR 03-AUG-1999; 99US-0147038.  
 PR 04-AUG-1999; 99US-0147204.  
 PR 04-AUG-1999; 99US-0147302.  
 PR 05-AUG-1999; 99US-0147192.  
 PR 05-AUG-1999; 99US-0147260.  
 PR 06-AUG-1999; 99US-0147303.  
 PR 06-AUG-1999; 99US-0147416.  
 PR 09-AUG-1999; 99US-0147493.  
 PR 09-AUG-1999; 99US-0147935.  
 PR 10-AUG-1999; 99US-0148171.  
 PR 11-AUG-1999; 99US-0148319.  
 PR 12-AUG-1999; 99US-0148341.  
 PR 13-AUG-1999; 99US-0148565.  
 PR 13-AUG-1999; 99US-0148684.  
 PR 16-AUG-1999; 99US-0149368.  
 PR 17-AUG-1999; 99US-0149175.  
 PR 18-AUG-1999; 99US-0149426.  
 PR 20-AUG-1999; 99US-0149722.  
 PR 20-AUG-1999; 99US-0149723.  
 PR 20-AUG-1999; 99US-0149929.  
 PR 23-AUG-1999; 99US-0149902.  
 PR 23-AUG-1999; 99US-0149930.  
 PR 25-AUG-1999; 99US-0150566.  
 PR 26-AUG-1999; 99US-0150884.  
 PR 27-AUG-1999; 99US-0151065.  
 PR 27-AUG-1999; 99US-0151066.  
 PR 27-AUG-1999; 99US-0151080.  
 PR 30-AUG-1999; 99US-0151303.  
 PR 31-AUG-1999; 99US-0151438.  
 PR 01-SEP-1999; 99US-0151930.  
 PR 07-SEP-1999; 99US-0152363.  
 PR 10-SEP-1999; 99US-0153070.  
 PR 13-SEP-1999; 99US-0153758.

PR 15-SEP-1999; 99US-0154018.  
 PR 16-SEP-1999; 99US-0154039.  
 PR 20-SEP-1999; 99US-0154779.  
 PR 22-SEP-1999; 99US-0155139.  
 PR 23-SEP-1999; 99US-0155486.  
 PR 24-SEP-1999; 99US-0155659.  
 PR 28-SEP-1999; 99US-0156458.  
 PR 29-SEP-1999; 99US-0156596.  
 PR 04-OCT-1999; 99US-0157117.  
 PR 05-OCT-1999; 99US-0157753.  
 PR 06-OCT-1999; 99US-0157865.  
 PR 07-OCT-1999; 99US-0158029.  
 PR 08-OCT-1999; 99US-0158232.  
 PR 12-OCT-1999; 99US-0158369.  
 PR 13-OCT-1999; 99US-0159293.  
 PR 13-OCT-1999; 99US-0159294.  
 PR 13-OCT-1999; 99US-0159295.  
 PR 14-OCT-1999; 99US-0159329.  
 PR 14-OCT-1999; 99US-0159330.  
 PR 14-OCT-1999; 99US-0159331.  
 PR 14-OCT-1999; 99US-0159637.  
 PR 14-OCT-1999; 99US-0159638.  
 PR 18-OCT-1999; 99US-0159584.  
 PR 21-OCT-1999; 99US-0160741.  
 PR 21-OCT-1999; 99US-0160767.  
 PR 21-OCT-1999; 99US-0160768.  
 PR 21-OCT-1999; 99US-0160770.  
 PR 21-OCT-1999; 99US-0160814.  
 PR 21-OCT-1999; 99US-0160815.  
 PR 22-OCT-1999; 99US-0160980.  
 PR 22-OCT-1999; 99US-0160981.  
 PR 22-OCT-1999; 99US-0160989.  
 PR 25-OCT-1999; 99US-0161404.  
 PR 25-OCT-1999; 99US-0161405.  
 PR 25-OCT-1999; 99US-0161408.  
 PR 26-OCT-1999; 99US-0161359.  
 PR 26-OCT-1999; 99US-0161360.  
 PR 26-OCT-1999; 99US-0161361.  
 PR 28-OCT-1999; 99US-0161920.  
 PR 28-OCT-1999; 99US-0161921.  
 PR 28-OCT-1999; 99US-0161992.  
 PR 28-OCT-1999; 99US-0161993.  
 PR 29-OCT-1999; 99US-0162142.

Query Match 57.6%; Score 38; DB 21; Length 333;  
 Best Local Similarity 53.8%; Pred. No. 1.8e+02;  
 Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 CATLRVYKGGXA 13  
 |||:|:|:  
 Db 181 CAFLSIYQVGAA 193

RESULT 14  
 ABG29513  
 ID ABG29513 standard; Protein; 55 AA.  
 XX  
 AC ABG29513;  
 XX  
 DT 18-FEB-2002 (first entry)  
 XX  
 DE Novel human diagnostic protein #29504.  
 XX  
 KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200175067-A2.  
 XX  
 PD 11-OCT-2001.  
 XX  
 PF 30-MAR-2001; 2001WO-US08631.  
 XX

PR 31-MAR-2000; 2000US-0540217.  
PR 23-AUG-2000; 2000US-0649167.  
PA (HYSE-) HYSEQ INC.  
XX Drmanac RT, Liu C, Tang YT;  
PI WPI; 2001-639362/73.  
XX N-PSDB; AAS93700.  
XX New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity  
XX  
XX Claim 20; SEQ ID NO 59872; 103pp; English.  
XX  
XX The invention relates to isolated polynucleotide (I) and  
XX polypeptide (II) sequences. (I) is useful as hybridisation probes,  
XX polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
XX and gene mapping, and in recombinant production of (II). The  
XX polynucleotides are also used in diagnostics as expressed sequence tags  
XX for identifying expressed genes. (I) is useful in gene therapy techniques  
XX to restore normal activity of (II) or to treat disease states involving  
XX (II). (II) is useful for generating antibodies against it, detecting or  
XX quantitating a polypeptide in tissue, as molecular weight markers and as  
XX a food supplement. (II) and its binding partners are useful in medical  
XX imaging of sites expressing (II). (I) and (II) are useful for treating  
XX disorders involving aberrant protein expression or biological activity.  
XX The polypeptide and polynucleotide sequences have applications in  
XX diagnostics, forensics, gene mapping, identification of mutations  
XX responsible for genetic disorders or other traits to assess biodiversity  
XX and to produce other types of data and products dependent on DNA and  
XX amino acid sequences. ABG00010-ABG30377 represent novel human  
XX diagnostic amino acid sequences of the invention.  
XX Note: The sequence data for this patent did not appear in the printed  
XX specification, but was obtained in electronic format directly from WIPO  
XX at ftp.wipo.int/pub/published\_pct\_sequences.  
SQ Sequence 55 AA;  
Query Match 56.1%; Score 37; DB 22; Length 55;  
Best Local Similarity 70.0%; Pred. No. 41;  
Matches 7; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 2 ATLRYVKGG 11  
Db 12 AVFRVPGG 21  
RESULT 15  
ABU70842  
ID ABU70842 standard; Protein; 206 AA.  
XX AC ABU70842;  
XX  
XX 10-JUN-2003 (first entry)  
XX Human adipocyte Selected Interacting domain, SID, #473.  
XX Human; prey; adipocyte; SID; selected interacting domain;  
KW anorectic; antidiabetic; protein-protein interaction; diabetes;  
KW yeast 2-hybrid assay; metabolic disorder; obesity.  
XX  
XX Homo sapiens.  
XX  
XX WO200286122-A2.  
XX  
XX 31-OCT-2002.  
XX  
XX 14-MAR-2002; 2002WO-EP03768.  
XX  
XX 14-MAR-2001; 2001US-275734P.  
PR

XX (HYBR-) HYBRIGENICS.  
XX  
XX Legrain P, Daviet L;  
PI  
XX  
XX WPI; 2003-103412/09.  
XX N-PSDB; ACA57386.  
XX  
XX New complex between two interacting proteins in adipocyte cells, useful  
PT for identifying selected interacting domains that modulate protein  
PT interactions, or for preventing or treating metabolic disorders such as  
PT obesity or diabetes  
XX  
XX Claim 6; Page 266-267; 382pp; English.  
XX  
XX The invention relates to a complex between two interacting proteins in  
XX adipocyte cells, given in the specification. The proteins are identified  
XX by selecting a bait protein from a known adipocyte marker and then  
XX performing a yeast 2-hybrid selection to isolate prey proteins encoded by  
XX members of an adipocyte cDNA library. The proteins are designated SID  
XX (RTM) (selected interacting domains) proteins. Also included are a  
XX polynucleotide encoding a polypeptide in the adipocyte cells, a  
XX recombinant host cell expressing at least one of the interacting  
XX polypeptides of the complex, selecting a modulating compound in adipocyte  
XX cells, a SID (RTM) polypeptide comprising any of the 738 amino acid  
XX sequences given in the specification (including its fragment or variant),  
XX a SID (RTM) polynucleotide comprising any of the 738 nucleotide sequences  
XX given in the specification (including its fragment or variant), a vector  
XX comprising the SID (RTM) polynucleotide, a recombinant host cell  
XX comprising the vector, a protein chip comprising the polypeptides and  
XX a record comprising all or part of the data, listed in the specification.  
XX The complex, polypeptides, polynucleotides and compounds are  
XX useful for preventing or treating metabolic disorders such as obesity  
XX or diabetes. The polynucleotides are useful as probes or primers. The  
XX complex is particularly useful for identifying selected interacting  
XX domains (SID (RTM)) for screening drugs that modulate the protein  
XX interaction, thus exhibiting the therapeutic effect. The present  
XX sequence represents a SID (prey) protein of the invention.  
SQ Sequence 206 AA;  
Query Match 56.1%; Score 37; DB 24; Length 206;  
Best Local Similarity 60.0%; Pred. No. 1.7e+02;  
Matches 6; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
QY 1 CATLRVYKGG 10  
Db 17 CAVMRVHAGG 26

Search completed: August 28, 2003, 18:34:29  
Job time : 40.1818 secs